IMPACT OF AI IN DRUG DEVELOPMENT AND CLINICAL STUDIES: A SYSTEMATIC REVIEW

Vasim Mansur Aparadh*[1], Nitin Chandrakant Mohire [2], Gita Nitin Mohire[3], Ritesh Kumar[4], Abhijit Anil Gaikwad[5], Ravindra Bhimraj Laware[6], Tapan Kumar Mahato[7], Anagha Amit Sarvadnya[8]

[1]*Department of Pharmacology, Appasheb Birnale College of Pharmacy Sangali Maharashtra*

[2]*Principal, Shivajirao S. Jondhle college of Pharmacy, Asangaon, Tal Shahapur, Dist. Thane, Maharashtra- 421601*

[3]*Associate Professor, Navsahyadri Institute of Pharmacy, Naigaon, Nasarapur, Pune-412213*

[4] *Professor, Department of Pharmaceutics, Anand College of Pharmacy, Sharda Group of Institutions (SGI), Agra, Uttar Pradesh- 282007, India*

[5]*Assistant Professor, Nutan Vidya Prasarak Mandals Arts Commerce and Science College Lasalgaon, Niphad, Nashik, Maharashtra 422306*

[6]*Principal, College of Pharmaceutical Sciences, PIMS (DU), Loni (Bk)Tal Rahata, Dist. Ahmednagar, Maharashtra*

[7]*Sardar patel college of pharmacy, Sardar Patel education campus, Vidya Nagar-Vadtal Road, Bakrol, District Anand, Gujarat 388315, India*

[8]*SMES's Mahavir Institute of Pharmacy Nashik*

***Corresponding Author:** Vasim Mansur Aparadh

wasimaparadh1@gmail.com

Abstract

The pharmaceutical business might undergo a huge change if artificial intelligence (AI) and machine learning (ML) are effectively used in drug research. These tools have the potential to hasten the discovery of novel medicinal compounds, the prediction of their efficacy and toxicity, and the improvement of medication design. This potential do, however, come with a number of difficulties and constraints that need to be properly taken into account. Using examples from illness diagnostics, compound efficacy prediction, toxicity assessment, drug-drug interaction prediction, and compound design, this article examines the varied terrain of AI in drug development. Data quality issues, ethical dilemmas, and possible biases are emphasised as obstacles. To deal with these issues, approaches like explainable AI and data augmentation are suggested. It is emphasised that AI should be seen as a supplemental tool, increasing human researchers' skills rather than taking the place of their knowledge. The pharmaceutical industry may usher in a new age of quicker drug discovery and development by overcoming these obstacles and utilising AI's strengths.

Keywords: Artificial intelligence, machine learning, drug discovery, compound efficacy prediction, toxicity assessment, drug-drug interactions.

DOI: 10.48047/ecb/2023.12.Si11.044

1. INTRODUCTION

The beyond a decade have seen a blast in machine learning (ML) and artificial intelligence (simulated intelligence), because of critical improvements in PC innovation. The ability to accumulate and dissect gigantic measures of data has radically worked on accordingly. In the meantime, it has become restrictively costly to acquaint new prescriptions with the market and to patients. In the leftover areas of this article, we allude to "Research and development" to comprehensively allude to the examination, science, and systems associated with making new medications, from drug revelation through clinical turn of events and testing to life-cycle the executives. The accompanying assessments show that making another medication is a troublesome, costly strategy with an unfortunate achievement rate: A medication's middle improvement length ranges from 5.9 to 7.2 years for non-oncology and 13.1 years for oncology, with a typical Research and development spend of $1.3 billion for each medication [1] and a 13.8% endorsement rate for all medication improvement programs [2]. The medication research business is drawn to simulated intelligence/ML approaches in view of their robotized nature, prescient powers, and the subsequent expected gain in effectiveness. Making drug research more productive will without a doubt help patients and organizations the same by reducing expenses, accelerating improvement, and raising the probability of progress (POS). For the beyond 15 to 20 years, ML procedures have been applied in drug advancement with developing complexity. Clinical preliminary plan, tasks, and investigation are the latest areas of medication research where positive interruption welcomed on by simulated intelligence/ML is starting to occur. Because of a developing reliance on computerized advancements for patient data gathering, the Coronavirus pandemic mightadditionally speed up the utilization of simulated intelligence/ML in clinical preliminaries. In this work, we try to give a wide outline of the ongoing circumstance of man-made intelligence/ML in drug improvement and to propose a few novel regions where an enormous impact might be conceivable. We guess that this paper will give a decent perspective, help with recognizing publicity from the real world, and eventually illuminate and empower the best use of man-made intelligence/ML.

2. AI IN DISEASE DIAGNOSIS

Sickness examination becomes fundamental for fostering a smart therapy plan and guaranteeing patients' prosperity. Precise conclusion is hampered by human blunder, and misjudging of the created data makes the work troublesome and tedious. By guaranteeing precision and productivity, man-made intelligence might be applied in various ways. Following an exhaustive survey of the writing, utilizations of different innovations and approaches for sickness determination have been reported. As indicated by a few ecological articulations, the interest for the medical care framework continually develops as the human populace grows [3].

The improvement of new techniques can characterize the pertinence by representing the ongoing existing situation that has not been covered, regardless of the presence of powerless,

incongruous, non-investigating incoherencies, as indicated by a significant measure of proof [4, 5, and 6]. The seriousness of a patient's sickness weight ought to be thought about while ordering them, and man-made intelligence can assume a critical part in finding [7]. At the point when one gets a finding, their illness is given a name in light of explicit precursor issues[8]. It is generally fitting to monitor every patient's wellbeing report structure to arrange most of assessments that come from directing tests and tests. The ideal choices are made in view of data accumulated, essentially corresponding to the clinical necessities for a brief determination. The examination is exclusively at the doctors' caution and is liable to change [9]. One needs to focus on simulated intelligence for recognizable proof and assurance of the early prescient phase of the sickness more than the therapy or symptomatic stage because of the accessibility of different analytic philosophies that are causing trust concerns. Such a determination can help with the beginning of early treatment, which can bring about both perceptible enhancements in the patients and expanded viability of computer-based intelligence modules [10, 11]. Nowadays, profound learning, brain systems administration, and calculations-based innovation would be broadly utilized for the distinguishing proof, extraction, and catering of the relative multitude of assembled data. The two principal illnesses where artificial intelligence has acquired significance are malignant growth and dementia [12, 13]. In the event that calculations are not self-produced or have never been connected to any recently gathered data, they can never be one-sided. A relevant and special dataset is required for measurable management [14, 15, and 16]. The unmistakable quality of the found groups, as opposed to the client's feedback, decides acknowledgment [17]. Unsupervised learning can be utilized to analyze hepatitis [18]. Be that as it may, by making various developmental changes and altering assumptions, profound learning relationships can be achieved [19, 20]. Bigger data sets and various sections regularly support simulated intelligence's appropriateness [21, 22], yet the outcomes are vast [23, 24]. The order of dermatological sicknesses and the recognition of atrial fibrillation are two instances of profound learning in diagnostics among numerous others [25, 26]. For the assessment of calculations, cross-approval can be utilized to haphazardly divide data into numerous sets [27]. The normal estimations of artificial intelligence put extraordinary accentuation on three pivotal perspectives: exactness, responsiveness, and particularity [28].

Utilizing support vector machines, closest neighbors, irregular woodlands, choice trees, calculated relapse, credulous bayes, segregate examination, and convolution brain organizations to direct profound learning organizations and brain processes, clinical viewpoints can create brings about a more far-reaching way founded on writing investigation. The beginning, example size, and number of elements in the preparation and testing tests can be generally used to perform calculation-based execution driven examination. Choice trees and thinking were consolidated in the analysis of liver illnesses [29]. Prescient demonstrating was the subject of various examinations,

which were obvious in their capacity to conjecture the beginning of Parkinson's illness [30]. To analyze lung illnesses, the rib division calculation was made [31]. Because of various disadvantages, customary techniques are not successful for rib-wise portioning X-beam pictures. In this review, a calculation was made by adding unpaired examples to chest X-beam pictures of pneumonia patients. A multi-scale network then, at that point, took in the properties of the pictures. As per the review, this strategy performs well with further developed rib division and might be useful in the determination of cellular breakdown in the lungs and other lung issues [32]. Specialists have as of late utilized calculations and machine learning to arrange and distinguish heart arrhythmias by investigating ECG data. [33]. In an alternate report, the enhancement genetic algorithm (GA) and support vector machine (SVM) classifier were utilized to order and analyze TB.

3. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY

Processes for drug disclosure and advancement might be changed by expanded handling limit and the making of novel computer-based intelligence devices. The drug business is currently managing decreases in the viability of its medicine improvement programs and simultaneous expansions in innovative work consumptions. The drug area has encountered a huge development in the digitization of data as of late; one continuous trouble is to really assemble, look at, and use this data to address muddled clinical difficulties. With further developed computerization, simulated intelligence can deal with huge measures of data. To help efficiency and proficiency, it might likewise consolidate and apply machine learning procedures. The essential utilizations of man-made intelligence to improve the effectiveness of the medication disclosure cycle are shrouded in this part. Drug plan, polypharmacology, drug reusing, and drug screening are the four portions that might be genuinely isolated into drug disclosure. The principal utilization of computer-based intelligence is in drug property expectation, which might kill the requirement for clinical preliminaries and human examination subjects, which is worthwhile from a monetary and moral viewpoint. This segment talks about the papers found in the audit that back the consolidation of simulated intelligence into the medication revelation process to build efficiency, precision, and proficiency.

Utilizing a ResNet brain organization, Cui and Zhu [34] researched whether computer-based intelligence can foresee the physicochemical qualities (dissolvability, parcel coefficient, and separation steady) of a few drugs. When contrasted with past non-computer-based intelligence-based models, this organization was more exact in anticipating the solvency of the atoms as confirmed by the upgraded yield and diminished extraction season of polysaccharides from different sources. This exhibited how simulated intelligence might be incorporated into the prescription advancement cycle to build its viability. Lusci and partners [35] directed a second examination to show the worth of artificial intelligence in this present circumstance, testing in the event that a recursive brain organization could gauge the solvency of different synthetic and natural mixtures in water. In the concentrate by Cui and Zhu, it was found that the computer-based intelligence model gave

discoveries that were more precise than those achieved utilizing customary techniques, demonstrating its worth in drug improvement. Polykovskiy and partners' work [36], which took a gander at the capacity of man-made intelligence to expect the action of different integrated compounds, is one more illustration of how computer-based intelligence might increment productivity. The objective was to determine whether using simulated intelligence, the unwavering quality of the medication screening interaction could be worked on by expanding exactness. To estimate movement, an ill-disposed auto-encoder was utilized. The discoveries created utilizing a repetitive brain network-based generative model methodology contrast from those got with the once more sub-atomic plan to produce irregular medication like mixtures and one more to create target-one-sided compounds, showing that the two methodologies might be used related to each other. Furthermore, it gave significant subtleties on the particle target, enlightening the way that computer-based intelligence increments procedural accuracy and effectiveness as well as works with new disclosures. One more exploration by Daynac and partners [29] researched assuming artificial brain organizations may be utilized to foresee the antibacterial attributes of different mixtures, making the method speedier, more affordable, and more precise. That's what the results showed, with an exceptionally little mistake edge of 10 mm, the brain network appropriately anticipated over 70% of the antibacterial movement. Also, it had the option to figure the way of behaving of a few particles all the while, what cut down on how much time required for handling overall. Pu and associates' exploration is the latest one in our writing survey to



Fig 1: Impact of AI in drug discovery and clinical trails

cover the utility of artificial intelligence. The creators looked to speed up the ongoing method and get rid of the requirement for clinical preliminaries by utilizing a simulated intelligence program, eToxPred, to gauge the levels of harmfulness of different engineered and organic synthetics. The results showed that the man- made intelligence model was adequately precise to potentially supplant clinical preliminaries since it could accurately foresee the unsafe characteristics over 72% of the time with just a 4% complete blunder rate [30].

4. TOOLS OF AI

Robotic pharmacy: The UCSF Clinical Center utilizes mechanical innovation for the creation and checking of drugs determined to upgrade patient security. They guarantee that the framework has precisely pre-arranged 3,50,000 dosages of medication. The robot has demonstrated to be fundamentally better than people as far as size and its ability to direct exact medications. The production of dangerous chemotherapy drugs for oral and injectable use is one of the abilities of automated innovation. The UCSF physicists and medical attendants presently have more opportunity to zero in on furnishing direct quiet consideration and teaming up with the specialists, permitting them to take advantage of their insight. [39]

a) **MEDi Robot:** An abbreviation for clinical and designing planning intelligence, MEDi is a robot. Simulated intelligence based toolsThe people group wellbeing sciences teacher at the College of Calgary in Alberta, Tanya Beran, filled in as the undertaking chief for the making of the aggravation the executives robot. In the wake of working in clinics where youngsters cry during operations, she had the idea. Albeit the robot can't think, plan, or reason, it very well might be intended to seem to have man-made intelligence by advising the children what's in store during a clinical treatment after first laying out a bond with them.

b) **Erica robot:** Teacher at Osaka College Hiroshi Ishiguro made Erica, a pristine consideration robot, in Japan. It was made in relationship with Kyoto College, the High level Broadcast communications Exploration Organization Worldwide (ATR), and the Japan Science and Innovation Office. It has a blend of European and Asian face includes and communicates in Japanese. It appreciates watching animation films, needs to go to Southeast Asia, and wants a daily existence accomplice who will talk with it, very much like some other regular individual. The robot was made with the capacity to comprehend and answer requests with human-like looks, however it can't uninhibitedly move. Ishiguro fixed up the elements of 30 appealing ladies and used the normal to develop the robot's nose, eyes, and different characteristics, making Erica the "most lovely and insightful" android.

c) **Robots TUG:** Robots called Aethon Pull are made to independently move around the emergency clinic and transport huge things like junk and material as well as solutions, dinners,

examples, and assets. It highlights two adaptations, including trade base stages that might be utilized to ship racks, containers, and trucks, as well as fixed and gotten trucks. Conveyances of medications, sensitive things, and lab examples are made utilizing fixed trucks; notwithstanding, trade stages are used all thingsconsidered.

5. ADVANCED TECHNOLOGIES IN DRUG DISCOVERY

To aid drug disclosure and medication produce, different advances and approaches are currently utilized in the drug areas, as per the aftereffects of our writing search. The in silico absorption, distribution, metabolism, and excretion (ADMET) (Bayer, Leverkusen, Germany) is one of these advancements. For the development of novel pharmacological mixtures, this strategy reenacts pharmacokinetic and physicochemical endpoints [40]. The utilization of this innovation should hypothetically be possible utilizing two altogether different methods. The first assesses these discoveries comparable to collaborations between pertinent synthetic substances and indicated proteins [40]. This method has the detriment of requiring a solitary protein with impacts that are straightforwardly associated with the ADMET targets, like changes in comprehension, security, and assessed cost-viability. It is additionally important to picture the protein under assessment in top quality and in three aspects (3D). The subsequent strategy includes gathering auxiliary data for different various mixtures used to blend proteins in view of the previously mentioned boundaries, and examining it. In view of this data, complex/half and half profound learning models can be made with the guide of machine learning calculations and simulated intelligence [40]. This strategy requires a ton of manual upkeep and carefulness, however; even minor plan blunders can bring about exorbitant and tedious mistakes in discoveries and ends. This technique consumes a large chunk of the day to finish in any event, when everything works out positively since a great deal of data should be physically watched, evaluated, and disposed of [40]. Blockchain is one more piece of innovation used in the drug area. Blockchain is the name of a specific kind of data structure that depends on get-together and gathering records into blocks, which are then associated with each other in sequential request to shape a chain. Blockchain might be utilized in the drug area because of different highlights. These qualities incorporate steadiness, decentralization, clearness, and conspicuousness [41]. Perpetual quality depicts how the data on the blockchain can't be changed or modified. Decentralization alludes to the chance of a framework's data dealing with being taken care of by various associations. The expression "straightforwardness" alludes to the way that a blockchain's data is straightforward and that any client might inspect everything. The limit of a blockchain client to follow the data contained in the blockchain with verifiable timestamps is known as recognizeability. These components make it feasible for drug makers to analyze and screen their data and exchanges whenever [41] in the drug business. A few investigations have discovered that blockchain hasworked on the productivity of medication testing and clinical preliminaries, as well as the

viability and straightforwardness of drug organizations' stockpile chains [41]. However, blockchain has specific disadvantages. For instance, since it is a novel and state of the art innovation, it has high establishment and upkeep expenses that are inconceivable for more modest organizations, which restricts its utilization. Because of the significant expense, just an extremely small level of the populace approaches and information on this sort of innovation, which limits its application to additional wealthy areas. Thusly, there is even more work to be finished before expensive innovations like blockchain can be all the more broadly used to understand their huge commitment [41]. 3D printing is a third state of the art development that is presently applied in the drug area [42]. Since blue light has a more noteworthy capacity to send impedance than white light, further developed utilizations of this innovation use it to further develop exactness. These improvements consider the ever- evolving design of thing proliferation; besides, in light of the fact that to the far reaching openness and convenience of complex 3D printing, a wide assortment of people and enterprises are presently ready to create products locally and on request [43].



Fig 2: Use of AI in advance drug discovery and clinical trial

6. ROLE OF ML IN PREDICTING DRUG EFFICACY AND TOXICITY

Anticipating the adequacy and harmfulness of new restorative atoms is one of the fundamental purposes of artificial intelligence in restorative science. Customary ways to deal with drug improvement often depend on work and time-serious testing to assess a compound's expected consequences for the human body. The strategy might be long and costly, and the results are much of the time cloudy and truly factor. These limitations can be addressed by man-made intelligence strategies like machine learning. ML calculations can detect examples and patterns in light of the investigation of a ton of data that might get away from the notification of human specialists. When contrasted with utilizing customary methods, this can make it conceivable to propose novel bioactive substances with the least conceivable adverse consequences [44]. A DL calculation, for example, was as of late prepared utilizing a dataset of notable pharmacological particles and their important organic exercises. The action of new mixtures could then be precisely anticipated by the calculation. Based on broad preparation and the utilization of huge databases of known perilous and non-poisonous synthetics, significant commitments to the anticipation of harmfulness of imminent helpful mixtures have additionally been distributed. The identification of medication drug cooperations that happen when numerous meds are utilized for something similar or various circumstances in similar patient, prompting changed impacts or unfavorable reactions, is one more critical utilization of artificial intelligence in drug advancement. By examining gigantic databases of known medicine collaborations and distinguishing examples and patterns, simulated intelligence based procedures can decide this. A ML strategy has as of late been created to appropriately expect the connections of new drug pairings, which resolves this issue. With regards to customized medication, the utilization of artificial intelligence torecognize potential medication drug communications is especially relevant, taking into consideration the formation of specific treatment regimens that decrease the probability of negative aftereffects. The objective of customized medication is to change a patient's consideration to their novel qualities, including their hereditary cosmetics and response to drugs. The previously mentioned models show how artificial intelligence might be utilized in drug exploration to all the more precisely expect the adequacy and harmfulness of conceivable restorative atoms. This could work with the production of more secure, more powerful meds while additionally rushing the medication disclosure process [45].

7. THE IMPACT OF AI ON THE DRUG DISCOVERY PROCESS ANDPOTENTIAL COST SAVINGS

The formation of new mixtures with exact elements and exercises is one huger way that computer based intelligence is being utilized in the medication advancement process. The recognizable proof and change of as of now existing particles is a commonstay of ordinary strategies, however it very well might be a tedious and work concentrated methodology. Then again, man-made intelligence based strategies can work with the speedy and viable formation of new mixtures with helpful attributes and exercises. As a delineation of the

capability of these methods for the speedy and compelling plan of new medication competitors, a deeplearning (DL) calculation was as of late prepared on a dataset of realized drug compounds and their relating properties to propose new restorative molecules10 with wanted qualities, like solvency and action. With the making of AlphaFold, a notable programming stage for growing comprehension we might interpret science, Profound Psyche as of late made a significant commitment to the area of simulated intelligence research. A strong program gauges the matching three-layered structures from protein succession data and simulated intelligence [46]. It is guessed that this advancement in primary science would change drug revelation and customized treatment. The use of computer based intelligence in primary science and, by and large, in the existence sciences has progressed fundamentally with the advancement of AlphaFold. Once more medication configuration is using ML strategies and Sub-atomic Elements reproductions to build adequacy and accuracy. To profit from their corresponding assets, these procedures are being concentrated in combination20. This attempt is moreover supported by the use of interpretable machine learning (IML) and profound learning procedures. Specialists may now make meds more effectively and productively than any other time by joining the capacities of artificial intelligence and MD.

8. CHALLENGES AND LIMITATIONS OF USING AI IN DRUG DISCOVERY

Regardless of the expected benefits of artificial intelligence in drug disclosure, there are various hardships and limitations that should be considered. Admittance to appropriate data is one of the significant obstructions. Man-made intelligence based techniques frequently should be prepared on a huge measure of data. The accessibility of adequate data or the quality or consistency of the accessible data can habitually affect the accuracy and trustworthiness of the results. The moral issues are one more hindrance since man-made intelligence based frameworks could lead to questions about decency and bias. Expectations made utilizing a machine learning calculation, for example, might be uncalled for or wrong inthe event that the data used to prepare the framework is one-sided or unrepresentative. An imperative issue that must be tended to is guaranteeing the moral and impartial use of man- made intelligence for the making of novel restorative particles. There are various strategies and methods that might be applied to move past the difficulties artificial intelligence in substance medication faces [47]. Data augmentation46 is one system, which is the making of engineered data to improve existing datasets. This might work on the volume and assortment of data available for ML calculation preparing, thus upgrading the exactness and trustworthiness of the results. An alternate procedure is the utilization of reasonable computer based intelligence (XAI) methods48, which try to offer noticeable and fathomable legitimizations for the expectations delivered by ML calculations. This can support settling issues with predisposition and reasonableness in man-made intelligence based methods [48] and help to explain the hidden standards and assumptions used to make the expectations. Ebb and flow artificial intelligence based innovations can't

supplant human analysts' information and experience, nor could they at any point supplant laid out exploratory methods. Man-made intelligence can make expectations in view of the data that is right now available, and human specialists should assess and decipher the discoveries. The most common way of finding new medications can be improved by joining computer based intelligence with ordinary trial procedures. The most common way of finding novel medications can be advanced rapidly by consolidating the prescient capacity of man-made intelligence with the information and experience of human specialists [49] [50].

9. CONCLUSION

The landscape of pharmaceutical research and development may change as a result of the use of artificial intelligence (AI) and machine learning (ML) in drug discovery. The use of AI in illness diagnostics, medication effectiveness and toxicity prediction, and chemical design optimisation has shown promise in expediting the formerly time-consuming and expensive drug discovery process. The use of AI in this field is not without its difficulties, though. Quality and availability of data continue to be major obstacles. The success of AI depends on large and diverse datasets, and overcoming data constraints is essential for precise predictions. Thorough examination is required of ethical factors, notably prejudice and fairness. For equal healthcare results and to sustain public trust, AI models must be open, objective, and fair. These issues may be addressed using techniques like explainable AI and data augmentation. Limited datasets are supplemented via data augmentation, which improves the effectiveness of AI models. Explainable AI techniques provide insight into the decision-making process, allaying worries about the "black box" nature of AI. AI-driven insights combined with domain expertise are still crucial for successful medication development and well-informed decision-making. The pharmaceutical business can create a future where drug development is quicker, more effective, and morally responsible by utilising AI's advantages while being aware of its limits. To fully utilise AI's potential in influencing the future of healthcare as technology develops, it will be essential to strike the correct balance between innovation and accountability.

ACKNOWLEDGEMENT

Thanks to my all the faculty members for their support over the course of writing andpublication.

CONFLICT OF INTEREST

No conflict of interest

FUNDING

None

REFERENCES

1. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. doi: 10.1016/j.jhealeco.2016.01.012.
2. Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20(2), 273–286. doi: 10.1093/biostatistics/kxx069.
3. Menschner, P., Prinz, A., Koene, P., Köbler, F., Altmann, M., Krcmar, H., & Leimeister, J. M. (2011). Reaching into patients' homes—Participatory designed AAL services: The case of a patient-

centered nutrition tracking service. Electronic Markets,21, 63–76.

4. Okoli, C. (2015). A guide to conducting a standalone systematic literature review. Communications of the Association for Information Systems, 37, 879–910.
5. Paré, G., Trudel, M.-C., Jaana, M., & Kitsiou, S. (2015). Synthesizing information systems knowledge: A typology of literature reviews. Information Management, 52, 183–199.
6. Grant, M. J., & Booth, A. (2009). A typology of reviews: An analysis of 14 review types and associated methodologies. Health Information and Libraries Journal, 26, 91–108.
7. Ransohoff, D. F., & Feinstein, A. R. (1978). Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. New England Journal of Medicine, 299, 926–930.
8. Jutel, A. (2009). Sociology of diagnosis: A preliminary review. Sociology of Health & Illness, 31, 278–299.
9. Chang, C. L., & Hsu, M. Y. (2009). The study that applies artificial intelligence and logistic regression for assistance in differential diagnostic of pancreatic cancer. Expert Systems with Applications, 36, 10663–10672.
10. Obeng, O., & Paul, S. (2019). Understanding HIPAA compliance practice in healthcare organizations in a cultural context. In Proceedings of the 25th Americas Conference on Information Systems 2019, Cancún, Mexico.
11. Spohrer, J., & Banavar, G. (2017). Cognition as a service: An industry perspective. AI Magazine, 36, 71–86.
12. Mazzocco, T., & Hussain, A. (2012). Novel logistic regression models to aid the diagnosis of dementia. Expert Systems with Applications, 39, 3356–3361.
13. Lu, J., Song, E., Ghoneim, A., & Alrashoud, M. (2020). Machine learning for assisting cervical cancer diagnosis: An ensemble approach. Future Generation Computer Systems, 106, 199–205.
14. Solan, Z., Horn, D., Ruppin, E., & Edelman, S. (2005). Unsupervised learning of natural languages. Proceedings of the National Academy of Sciences, USA, 102, 11629–11634.
15. Karpischek, S., Michahelles, F., & Fleisch, E. (2014). Detecting incorrect product names in online sources for product master data. Electronic Marketing, 24, 151–160.
16. Deo, R. C. (2015). Machine learning in medicine. Circulation, 132, 1920–1930.
17. Alanazi, H. O., Abdullah, A. H., & Qureshi, K. N. (2017). A critical review for developing accurate and dynamic predictive models using machine learning methods in medicine and health care. Journal of Medical Systems, 41, 69.
18. Singh, A., Mehta, J. C., Anand, D., Nath, P., Pandey, B., & Khamparia, A. (2020). An intelligent hybrid approach for hepatitis disease diagnosis: Combining enhanced k-means clustering and improved ensemble learning. Expert Systems, 38, e12526.
19. Goodfellow, I., Bengio, Y., & Courville, A. (2016). Deep Learning, 1st ed. MIT Press.
20. Fogassi, L., Ferrari, P. F., Gesierich,

B., Rozzi, S., Chersi, F., & Rizzolatti, G. (2005). Neuroscience: Parietal lobe: From action organization to intention understanding. Science, 308, 662–667.

21. LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. Nature, 521, 436–444. doi: 10.1038/nature14539.
22. Jain, A., Mao, J., & Mohiuddin, K. (1996). Artificial neural networks: A tutorial. Computer, 29, 31–44.
23. Rudin, C. (2019). Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nature Machine Intelligence, 1, 206– 215.
24. Mishra, S., Yamasaki, T., & Imaizumi, H. (2018). Supervised classification of dermatological diseases by deep learning. arXiv:1802.03752.
25. Jin, Y., Qin, C., Huang, Y., Zhao, W., & Liu, C. (2020). Multi-domain modeling of atrial fibrillation detection with twin attentional convolutional long short-term memory neural networks. Knowledge-Based Systems, 193, 105460.
26. Wong, T. T. (2015). Performance evaluation of classification algorithms by k-fold and leave-one-out cross-validation. Pattern Recognition, 48, 2839–2846.
27. Ben-David, A. (2008). Comparison of classification accuracy using Cohen's weighted Kappa. Expert Systems with Applications, 34, 825–832.
28. Sokolova, M., & Lapalme, G. (2009). A systematic analysis of performance measures for classification tasks. Information Processing & Management, 45, 427–437.
29. Lin, R. H. (2009). An intelligent model for liver disease diagnosis. Artificial Intelligence in Medicine, 47, 53–62.
30. Prashanth, R., Roy, S. D., Mandal, P. K., & Ghosh, S. (2016). High-accuracy detection of early Parkinson's disease through multimodal features and machine learning. International Journal of Medical Informatics, 90, 13–21.
31. Wang, H., Zhang, D., Ding, S., Gao, Z., Feng, J., & Wan, S. (2021). Rib segmentation algorithm for X-ray image based on unpaired sample augmentation and multi-scale network. *Neural Computing and Applications, 1–15.
32. Qaisar, S. M., Khan, S. I., Srinivasan, K., & Krichen, M. (2022). Arrhythmia classification using multirate processing metaheuristic optimization and variational mode decomposition. Journal of King Saud University—Computer and Information Sciences. Advance online publication.
33. Hrizi, O., Gasmi, K., Ben Ltaifa, I., Alshammari, H., Karamti, H., Krichen, M., Ben Ammar, L., & Mahmood, M. A. (2022). Tuberculosis disease diagnosis based on an optimized machine learning model. Journal of Health Engineering, 2022, 8950243.
34. Cui, R. B., & Zhu, F. (2021). Ultrasound modified polysaccharides: A review of structure, physicochemical properties, biological activities and food applications. Trends in Food Science & Technology, 107, 491–

508.

35. Lusci, A., Pollastri, G., & Baldi, P. (2013). Deep architectures and deep learning in chemoinformatics: The prediction of aqueous solubility for drug-like molecules. Journal of Chemical Information and Modeling, 53(7), 1563–1575.
36. Polykovskiy, D., Zhebrak, A., Vetrov, D., et al. (2018). Entangled Conditional adversarial autoencoder for de novo drug discovery. Molecular Pharmaceutics, 15(10), 4398–4405.
37. Daynac, M., Cortes-Cabrera, A., & Prieto, J. M. (2015). Application of artificial intelligence to the prediction of the antimicrobial activity of essential oils. Evidence-Based Complementary and Alternative Medicine, 2015, 561024.
38. Pu, L., Naderi, M., Liu, T., et al. (2019). eToxPred: A machine learning-based approach to estimate the toxicity of drug candidates. BMC Pharmacology and Toxicology, 20(1), 2.
39. University of California San Francisco. (2011). New UCSF Robotic Pharmacy Aims to Improve Patient Safety. Available from: https://www.ucsf.edu/news/2011/03/9510/new-ucsf-robotic-pharmacy-aims-improve- patient-safety.
40. Göller, A. H., Kuhnke, L., Montanari, F., et al. (2020). Bayer's in silico ADMET platform: A journey of machine learning over the past two decades. Drug Discovery Today, 25(9), 1702–1709.
41. [Abu-Elezz, I., Hassan, A., Nazeemudeen, A., et al. (2020). The benefits and threats of blockchain technology in healthcare: A scoping review. International Journal of Medical Informatics, 142, 104246. doi:10.1016/j.ijmedinf.2020.104246 .
42. Park, B. J., Choi, H. J., Moon, S. J., et al. (2018). Pharmaceutical applications of 3D printing technology: Current understanding and future perspectives. Journal of Pharmaceutical Investigation, 49(6), 575–585. doi:10.1007/S40005-018-00414-Y.
43. Zimmerling, A., & Chen, X. (2020). Bioprinting for combating infectious diseases. Bioprinting, 20, e00104. doi:10.1016/j.bprint.2020.e00104.
44. Mandal, L., & Jana, N. D. (2019). Prediction of active drug molecule using back- propagation neural network. In Proceedings of the 8th International Conference System Modeling and Advancement in Research Trends (SMART) 2019, Moradabad, India, 22–23 November 2019; pp. 22–26.
45. Hanson III, C. W., & Marshall, B. E. (2001). Artificial intelligence applications in the intensive care unit. Critical Care Medicine, 29, 427–435.
46. Fogel, D. B. (2000). What is evolutionary computation? IEEE Spectrum, 37, 26–32.
47. Whitley, D. (1994). A genetic algorithm tutorial. Statistical Computing, 4, 65–85.
48. Moore, K. L. (2019). Automated radiotherapy treatment planning. In Seminars in Radiation Oncology; WB Saunders: Philadelphia, PA,

USA, Volume 29, pp. 209–218.

49. Troulis, M., Everett, P., Seldin, E., Kikinis, R., & Kaban, L. (2002). Development of a three-dimensional treatment planning system based on computed tomographic data. International Journal of Oral and Maxillofacial Surgery, 31, 349–357.
50. Arimura, H., Soufi, M., Kamezawa, H., Ninomiya, K., & Yamada, M. (2019). Radiomics with artificial intelligence for precision medicine in radiation therapy. Journal of Radiation Research, 60, 150–157.